← LeaderboardsInvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Ensysce Biosciences, Inc.
La Jolla, CA
$26,337,469
Total funding
5
Grants
Funding over time
peak $8.5M · FY2012–25$10M$7.5M$5M$2.5M$0
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$26,337,469 · 5
By mechanism
UG3$10,592,211 · 2
U01$9,861,616 · 1
UH3$5,585,570 · 1
R43$298,072 · 1
Investigators at Ensysce Biosciences, Inc.
InvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Exposure= the full size of every grant they're on ($1M each).
Rising Stars
First grant in the last 5 yrs
Not enough data
Emerging Leaders
6–10 yrs in
Not enough data
All-Time
Most funded here, all years
Largest grants
R-methadone-TAAP/MPAR: an abuse deterrent methadone prodrug with overdose protection: Pre-Clinical Development and Phase 1 Clinical Trial$5,389,398
UG3 · FY2019 · DA
PF614-MPAR: clinical development of opioid with oral overdose protection$5,288,921
U01 · FY2025 · DA
PF614-MPAR: clinical development of opioid with oral overdose protection$4,572,695
U01 · FY2024 · DA
PF614 MPAR Abuse Deterrent opioid prodrug with overdose protection: Pre-Clinical Development and Phase 1 Clinical Trial$2,949,024
UG3 · FY2019 · DA
PF614 MPAR Abuse Deterrent opioid prodrug with overdose protection: Pre-Clinical Development and Phase 1 Clinical Trial$2,794,315
UH3 · FY2022 · DA
PF614 MPAR Abuse Deterrent opioid prodrug with overdose protection: Pre-Clinical Development and Phase 1 Clinical Trial$2,791,255
UH3 · FY2021 · DA
PF614 MPAR Abuse Deterrent opioid prodrug with overdose protection: Pre-Clinical Development and Phase 1 Clinical Trial$2,123,989
UG3 · FY2018 · DA
Optimization of SWCNT/siRNA complex formulation for tumor accumulation$298,072
R43 · FY2012 · CA
PF614 MPAR Abuse Deterrent opioid prodrug with overdose protection: Pre-Clinical Development and Phase 1 Clinical Trial$129,800
UG3 · FY2019 · DA